Premium
Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa
Author(s) -
Rodgers Kenneth J.,
Hume Peter M.,
Morris John G. L.,
Dean Roger T.
Publication year - 2006
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2006.03941.x
Subject(s) - levodopa , oxidative stress , tyrosine , in vivo , in vitro , oxidative phosphorylation , pharmacology , biochemistry , parkinson's disease , protein biosynthesis , chemistry , biology , medicine , disease , microbiology and biotechnology
Levodopa (L‐dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L‐dopa treatment may be detrimental, with some studies suggesting that L‐dopa may be neurotoxic. A potentially important mechanism whereby L‐dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L‐dopa into proteins by protein synthesis. L‐Dopa competes with tyrosine as a substrate in protein synthesis in vitro . We provide evidence that L‐dopa can also be incorporated into proteins in vivo . Blood from L‐dopa‐treated and ‐non‐treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein‐incorporated dopa quantified by HPLC. Levels of protein‐incorporated dopa were significantly increased in lymphocyte cell proteins from L‐dopa‐treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein‐incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein‐incorporated dopa could also be generated in the CNS. The accumulation of protein‐incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long‐term L‐dopa treatment.